Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Sexually Transmitted Diseases Diagnostic Market

ID: MRFR/HC/41834-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Sexually Transmitted Diseases (STD) Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Nucleic Acid Amplification Tests, Serology Tests, Rapid Diagnostic Tests, Polymerase Chain Reaction Tests), By Disease Type (Chlamydia, Gonorrhea, Syphilis, HIV, Herpes Simplex Virus), By End Users (Hospitals, Clinics, Laboratories, At-Home Testing), By Sample Type (Blood Samples, Urine Samples, Swab Samples, Tissue Samples) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Sexually Transmitted Diseases Diagnostic Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Test Type (USD Billion) | |
      1. 4.1.1 Nucleic Acid Amplification Tests | |
      2. 4.1.2 Serology Tests | |
      3. 4.1.3 Rapid Diagnostic Tests | |
      4. 4.1.4 Polymerase Chain Reaction Tests |
    2. 4.2 Healthcare, BY Disease Type (USD Billion) | |
      1. 4.2.1 Chlamydia | |
      2. 4.2.2 Gonorrhea | |
      3. 4.2.3 Syphilis | |
      4. 4.2.4 HIV | |
      5. 4.2.5 Herpes Simplex Virus |
    3. 4.3 Healthcare, BY End User (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Clinics | |
      3. 4.3.3 Laboratories | |
      4. 4.3.4 At-Home Testing |
    4. 4.4 Healthcare, BY Sample Type (USD Billion) | |
      1. 4.4.1 Blood Samples | |
      2. 4.4.2 Urine Samples | |
      3. 4.4.3 Swab Samples | |
      4. 4.4.4 Tissue Samples |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Abbott Laboratories (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Roche Diagnostics (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Thermo Fisher Scientific (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Siemens Healthineers (DE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Hologic, Inc. (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 BD (Becton, Dickinson and Company) (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Cepheid (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 bioMérieux (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Ortho Clinical Diagnostics (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TEST TYPE |
    7. 6.4 US MARKET ANALYSIS BY DISEASE TYPE |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY END USER |
    13. 6.10 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
    18. 6.15 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
    19. 6.16 UK MARKET ANALYSIS BY TEST TYPE |
    20. 6.17 UK MARKET ANALYSIS BY DISEASE TYPE |
    21. 6.18 UK MARKET ANALYSIS BY END USER |
    22. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
    26. 6.23 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
    30. 6.27 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY DISEASE TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY END USER |
    34. 6.31 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
    38. 6.35 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY DISEASE TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY END USER |
    47. 6.44 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY DISEASE TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY END USER |
    51. 6.48 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
    55. 6.52 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
    67. 6.64 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
    71. 6.68 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
    80. 6.77 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
    84. 6.81 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Test Type (USD Billion, 2025-2035)

  • Nucleic Acid Amplification Tests
  • Serology Tests
  • Rapid Diagnostic Tests
  • Polymerase Chain Reaction Tests

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Chlamydia
  • Gonorrhea
  • Syphilis
  • HIV
  • Herpes Simplex Virus

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Laboratories
  • At-Home Testing

Healthcare By Sample Type (USD Billion, 2025-2035)

  • Blood Samples
  • Urine Samples
  • Swab Samples
  • Tissue Samples

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions